ERS Publications Podcasts

Joan Soriano, director of the International Centre for Advanced Respiratory Medicine in Majorca, Spain, introduces two papers from the February 2011 ERJ, focusing on the genetics and clinical/psychological aspects of chronic obstructive pulmonary disease (COPD).

G.B. Migliori, director of the WHO Collaborating Centre for TB and Lung Diseases in Tradate, Italy, discusses advances in the diagnosis of TB, introducing two articles focusing on tuberculosis (TB) in the January 2011 issue of the ERJ.

G.B. Migliori, director of the WHO Collaborating Centre for TB and Lung Diseases in Tradate, Italy, discusses advances in the diagnosis of TB, introducing two articles focusing on tuberculosis (TB) in the January 2011 issue of the ERJ.

As part of the January issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy chief editor James Chalmers interviews the Anthony De Soyza (Newcastle University, Newcastle, UK) and Timothy Aksamit (Mayo Clinic, Rochester, MN, USA) about the RESPIRE1 and RESPIRE2 trials of ciprofloxacin in non-cystic fibrosis bronchiectasis. These two global phase III trials enrolled a total of 937 and test two dosing regimens tested (identical dose). The range of treatment estimates favours use of a ciprofloxacin dry powder inhaler (DPI), which was overall, well tolerated, with high compliance and an excellent safety profile. The ciprofloxacin DPI 14-day regimen gave a 144-day delay in the to time to first exacerbation and a 25% reduction in the frequency of exacerbations, and the 28-day regimen gave a 138-day delay in to time to first exacerbation and a 28% reduction in frequency of exacerbations.

As part of the January issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy chief editor James Chalmers interviews the Anthony De Soyza (Newcastle University, Newcastle, UK) and Timothy Aksamit (Mayo Clinic, Rochester, MN, USA) about the RESPIRE1 and RESPIRE2 trials of ciprofloxacin in non-cystic fibrosis bronchiectasis. These two global phase III trials enrolled a total of 937 and test two dosing regimens tested (identical dose). The range of treatment estimates favours use of a ciprofloxacin dry powder inhaler (DPI), which was overall, well tolerated, with high compliance and an excellent safety profile. The ciprofloxacin DPI 14-day regimen gave a 144-day delay in the to time to first exacerbation and a 25% reduction in the frequency of exacerbations, and the 28-day regimen gave a 138-day delay in to time to first exacerbation and a 28% reduction in frequency of exacerbations.